Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.43 USD
+0.08 (5.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Enlivex Therapeutics Ltd. has a market cap of $31.93M, which represents its share price of $1.35 multiplied by its outstanding shares number of 23.65M. As a small-cap company, ENLV's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ENLV 1.43 +0.08(5.93%)
Will ENLV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for October 23rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
Other News for ENLV
Enlivex Therapeutics (ENLV) Receives Continued Buy Rating with $13 Price Target | ENLV Stock News
Enlivex Therapeutics (ENLV) Completes Key Trial Stage for Allocetra
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data | ...
Enlivex reaffirms August 18 as target date for Phase II data announcement
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from Analyst | ENLV Stock News